(-0.05%) 5 476.00 points
(-0.09%) 38 784 points
(-0.01%) 19 919 points
(0.22%) $80.51
(1.33%) $2.83
(0.25%) $2 334.80
(-0.16%) $29.35
(-0.20%) $969.00
(0.01%) $0.932
(-0.18%) $10.63
(0.06%) $0.788
(-1.86%) $86.81
Live Chart Being Loaded With Signals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery...
Stats | |
---|---|
Šios dienos apimtis | 3.22M |
Vidutinė apimtis | 4.81M |
Rinkos kapitalizacija | 2.16B |
EPS | $-0.390 ( Q1 | 2024-05-09 ) |
Kita pelno data | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.75 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0140 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-14 | Secora Michael | Buy | 39 375 | Class A Common Stock |
2024-06-14 | Secora Michael | Sell | 15 000 | Class A Common Stock |
2024-06-13 | Secora Michael | Buy | 39 375 | Class A Common Stock |
2024-06-13 | Secora Michael | Sell | 15 000 | Class A Common Stock |
2024-06-13 | Secora Michael | Sell | 39 375 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-34.83 |
Last 99 transactions |
Buy: 624 622 | Sell: 1 318 069 |
Tūris Koreliacija
Recursion Koreliacija
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
SENEA | -0.809 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Recursion Koreliacija - Valiuta/Žaliavos
Recursion Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $44.58M |
Bruto pelnas: | $-6.51M (-14.61 %) |
EPS: | $-1.580 |
FY | 2023 |
Pajamos: | $44.58M |
Bruto pelnas: | $-6.51M (-14.61 %) |
EPS: | $-1.580 |
FY | 2022 |
Pajamos: | $39.68M |
Bruto pelnas: | $-8.59M (-21.66 %) |
EPS: | $-1.360 |
FY | 2021 |
Pajamos: | $10.18M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.658 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Recursion
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.